Yousif Capital Management LLC Sells 2,504 Shares of Amgen Inc. $AMGN

Yousif Capital Management LLC lessened its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 4.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 57,438 shares of the medical research company’s stock after selling 2,504 shares during the quarter. Yousif Capital Management LLC’s holdings in Amgen were worth $19,012,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of the business. West Family Investments Inc. boosted its position in shares of Amgen by 1.1% during the 3rd quarter. West Family Investments Inc. now owns 2,760 shares of the medical research company’s stock valued at $779,000 after acquiring an additional 30 shares during the last quarter. Viawealth LLC boosted its position in shares of Amgen by 0.4% during the 3rd quarter. Viawealth LLC now owns 7,168 shares of the medical research company’s stock valued at $2,023,000 after acquiring an additional 30 shares during the last quarter. LOM Asset Management Ltd boosted its position in shares of Amgen by 1.2% during the 3rd quarter. LOM Asset Management Ltd now owns 2,554 shares of the medical research company’s stock valued at $721,000 after acquiring an additional 30 shares during the last quarter. Sittner & Nelson LLC boosted its position in shares of Amgen by 0.4% during the 3rd quarter. Sittner & Nelson LLC now owns 7,276 shares of the medical research company’s stock valued at $2,053,000 after acquiring an additional 30 shares during the last quarter. Finally, ORG Partners LLC boosted its position in shares of Amgen by 0.6% during the 4th quarter. ORG Partners LLC now owns 5,398 shares of the medical research company’s stock valued at $1,767,000 after acquiring an additional 31 shares during the last quarter. Institutional investors own 76.50% of the company’s stock.

Amgen Stock Performance

Shares of NASDAQ AMGN opened at $340.00 on Wednesday. The stock has a market cap of $183.28 billion, a price-to-earnings ratio of 23.89, a P/E/G ratio of 3.45 and a beta of 0.47. The company has a current ratio of 1.14, a quick ratio of 0.90 and a debt-to-equity ratio of 5.78. Amgen Inc. has a 1-year low of $261.43 and a 1-year high of $391.29. The stock’s 50-day moving average is $363.28 and its 200 day moving average is $334.04.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, beating analysts’ consensus estimates of $4.76 by $0.53. The company had revenue of $9.87 billion for the quarter, compared to analysts’ expectations of $9.46 billion. Amgen had a return on equity of 148.37% and a net margin of 20.98%.Amgen’s revenue for the quarter was up 8.6% compared to the same quarter last year. During the same period last year, the firm posted $5.31 EPS. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, sell-side analysts anticipate that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be issued a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a dividend yield of 3.0%. The ex-dividend date of this dividend is Friday, May 15th. Amgen’s dividend payout ratio (DPR) is currently 70.84%.

Key Stories Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Positive Phase‑3 topline: Amgen announced TEPEZZA subcutaneous OBI met primary and key secondary endpoints with a 77% proptosis response — potentially broadening access and driving future revenue upside for an already marketed franchise. AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR SUBCUTANEOUS TEPEZZA
• Positive Sentiment: Analyst praise and buy‑case: Commentary and pieces (e.g., Seeking Alpha) frame Amgen as the better buy after the data, highlighting competitive advantages versus rival programs. Amgen’s Thyroid Eye Disease Data Rocks Rival Viridian…
• Positive Sentiment: RBC raises price target to $370 and maintains Outperform — a near‑term analyst upgrade that supports upside thesis. RBC Capital Adjusts Amgen Price Target
• Neutral Sentiment: Competitive nuance: Stifel notes Amgen’s topline beats Viridian on proptosis response but says Viridian’s SC injection profile could still differentiate commercially — competition remains meaningful. Stifel sees path towards differentiation for Viridian…
• Neutral Sentiment: Investor interest and valuation context: Zacks and Yahoo pieces flag heavy search/interest and reiterate Amgen’s value metrics and sector performance — useful for longer‑term framing but not immediate catalysts. Here’s Why Amgen (AMGN) is a Strong Value Stock
• Negative Sentiment: Mixed market reaction: Several outlets note AMGN shares fell intraday despite the positive TEPEZZA data, indicating investors are weighing adoption, reimbursement, injector logistics and any near‑term revenue/phasing uncertainty. Amgen Posts 77% Response In Thyroid Eye Disease Study
• Negative Sentiment: Volatility in peer stocks: Rival Viridian plunged after Amgen’s results, underscoring sector re‑rating risk and competitive uncertainty that can spill back into Amgen’s short‑term stock volatility. Viridian Therapeutics stock tumbles after Amgen Tepezza data

Wall Street Analyst Weigh In

AMGN has been the subject of a number of research analyst reports. The Goldman Sachs Group lifted their price target on Amgen from $403.00 to $415.00 and gave the company a “buy” rating in a research report on Wednesday, February 4th. Daiwa Securities Group lifted their price target on Amgen from $370.00 to $410.00 and gave the company an “outperform” rating in a research report on Tuesday, February 10th. Leerink Partners reiterated a “market perform” rating and set a $355.00 price target on shares of Amgen in a research report on Thursday, March 5th. Freedom Capital downgraded Amgen from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 12th. Finally, Barclays initiated coverage on Amgen in a research report on Friday, February 20th. They set an “equal weight” rating and a $350.00 price target for the company. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, thirteen have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $355.00.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.